Home > News > featured news > Faisal Belhoul joins forces with iGan Partners to launch US$250 million iGan Arabia fund to drive MedTech innovation in MENA

AI

Faisal Belhoul joins forces with iGan Partners to launch US$250 million iGan Arabia fund to drive MedTech innovation in MENA

iGan Partners | February 08, 2022

iGan Partners, Canada's leading healthcare technology investors, has joined forces with Faisal Belhoul, a Dubai-based investments professional and entrepreneur, to launch a US$250M iGan Arabia regional fund to drive MedTech innovation across the Middle East and North Africa region.

iGan Arabia will focus on investing in AI/Cloud-enhanced medical devices and digital health technologies that improve patient outcomes and reduce healthcare cost. The fund targets US$250M through limited partnerships with an additional US$250M in co-investments.

The first four investments have been identified to drive breakthrough MedTech in the region. These are Exact Imaging, the world's first micro-ultrasound for unmatched resolution of prostate cancer; Okadoc, the region's most advanced digital patient management solution; eSight Corporation, wearable electronic vision devices for legally blind people challenged by eye diseases; and MolecuLight, the world's first handheld imaging device enabling clinicians to visualize bacteria in real-time for advanced wound care. All these already have regulatory approval and are scaling world-wide.

H.E. Jean-Philippe Linteau, Consul General of Canada in Dubai and the Northern Emirates, commented: "I am pleased to see Canadian and UAE health innovation leaders partner together to create iGan Arabia. The UAE has proven to be an early adopter of innovation. This new partnership will help our healthcare technology companies grow and succeed globally."

"We see the GCC as a transformative healthcare region. We have identified and uncovered several innovative opportunities across Digital Health, Connected Medical Devices, Healthcare IT and Artificial Intelligence. These are sectors that iGan brings a lot of expertise and we understand what it takes for companies to scale and succeed. Through this first of its kind Fund, we will invest locally and will showcase the GCC's healthcare innovations to the world."

Sam Ifergan, Founder & CEO, iGan Partners

Faisal Belhoul, Co-Chairman, iGan Arabia, added: "Through iGan Arabia we aim to invest in start-ups and other healthcare companies, especially in the GCC, and help them evolve as the best-in-class. We will support not only their operations in the region but also help scale up their operations to key markets in North America, Europe, and LATAM. iGan Arabia will help establish GCC as a world-class MedTech hub that will create thousands of new jobs and add value to the economy."

Spotlight

FASTlab HPLC+

Learn more about the new FASTlab HPLC+. Efficient HPLC purification and reformulation in one. Increased flexibility and efficiency of R&D tracer production enabling nearly all compounds and synthesis methods. Integrated reformulation system enabling higher dilution volume and faster mixing to empower your clinical research.

More featured news

Spotlight

FASTlab HPLC+

Learn more about the new FASTlab HPLC+. Efficient HPLC purification and reformulation in one. Increased flexibility and efficiency of R&D tracer production enabling nearly all compounds and synthesis methods. Integrated reformulation system enabling higher dilution volume and faster mixing to empower your clinical research.

Related News

Health Technology, AI

WELL Health to Enter into Strategic Alliance with MCI Onehealth, Acquire Clinical Assets, and Invest in AI-Focused Data Science Business

PRNewswire | July 21, 2023

WELL Health Technologies Corp. a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that as of July 19, 2023 it has entered into an agreement to acquire clinic assets form MCI Medical clinics Inc., a subsidiary of MCI Onehealth Technologies Inc. (TSX: DRDR) ("MCI") and a subscription agreement for a convertible debenture financing in MCI which will strategically focus the MCI business around its leading AI, Data Science and Rare & Complex Disease Detection platform (the "Transaction"). "This is a major step for WELL and it's all about the power of Artificial Intelligence and how it can help solve some of the most difficult disease detection and diagnosis problems healthcare providers and patients face every day", said Hamed Shahbazi, Founder and CEO of WELL Health. "We're thrilled to enter into a number of agreements that result in a strategic alliance that will immediately position MCI OneHealth as a key national leader in the multi-billion dollar disease detection marketplace." Dr. Michael Frankel, Chief Medical Officer of WELL commented, "MCI's platform has already saved lives by discovering those 'needle in a haystack cases' and delivered value to hundreds of healthcare providers. As a physician I am excited to work with them to evolve their platform and help them expand their pool of participating physicians. I am also very excited to welcome the talented clinical staff of the clinics that will be joining the WELL Family." As part of the Transaction, WELL will acquire a significant portion of MCI's clinical assets, which are located in Southern Ontario and offer a range of primary care services, including family medicine, women's health, and other specialties. The acquisition brings more than 130 physicians to the WELL family, adding to over 3,000 providers in WELL's patient services business units across North America. The MCI clinics will be integrated with WELL's Ontario based clinic chain which is the largest owned and operated network of clinics in the province. WELL's Ontario clinics offer a breadth of care including primary care, diagnostics, allied health, and other medical subspecialties. The acquisition of these well-known and regarded primary care clinics in Ontario marks a significant milestone in WELL's national clinic expansion strategy. The clinics in this acquisition are expected to collectively contribute more than $21 million of annual revenue and are expected to contribute positive Adjusted EBITDA in 2024. Following the completion of the Transaction, WELL plans to integrate leading edge software and workflows, such as OceanMD's patient engagement tools, DoctorCare's RCM services, and WELL AI Voice, from its Practitioner Enablement Platform. WELL is also advancing a short-term bridge loan to MCI designed to ensure the company has the required resources to operate until the various transactions close. It is anticipated that closing shall occur on or around Oct 1, 2023. Once the Transaction closes, WELL will also have representation on MCI's board of directors. Upon closing of the Transaction, WELL will be a holder of MCI's convertible debentures, and shall subject to the satisfaction of certain conditions, have certain rights associated with call options granted by two shareholders of MCI for up to 30.8 million Class A Subordinate Voting Shares and 30.8 million Class B Multiple Voting shares of MCI's go-forward business. MCI plans to utilize the proceeds from this convertible debenture financing to advance their technology-enabled healthcare research offerings, placing a strong emphasis on harnessing the power of artificial intelligence for healthcare applications. This investment will be part of WELL's AI Investment Program1 where WELL stated that it will make meaningful investments in AI focused companies to help improve tools for providers and their patients. WELL is confident that our work in AI will meaningfully enhance our ESG goals and deliver societal value. Eight Capital acted as financial advisor to WELL Health in connection with the Transaction, and Clark Wilson acted as WELL Health's legal counsel. About WELL Health Technologies Corp. WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 28,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 130 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on the OTC Exchange under the symbol "WHTCF".

Read More

Medical Devices, Healthcare Analytics

Verséa Health, Inc. Launches Verséa Easy Lab™, Affordable, Highly Accurate Over-the-Counter (OTC) Product Line

businesswire | August 16, 2023

Verséa Health, Inc. (“Verséa”), a Florida-based health care company engaged in the commercialization of innovative diagnostics and therapeutics, has launched the Verséa Easy Lab™ product line of rapid, at-home, over-the-counter diagnostic tests that will be sold at retail locations nationwide. The affordable, FDA approved, and professional quality tests will enable people to check up on their health at any time and in the comfort of their homes. Verséa Easy Lab™ brings together for the first time a broad range of home use diagnostic test segments under one consumer driven national brand, and aims to put better, more rapid information on people’s health in their hands. Currently available tests provide nearly instant results and interpretation for: pregnancy, ovulation, iFOBT (colon health screening), and 6-panel drugs of abuse testing. James Olin, Chief Commercial Officer at Verséa Health, Inc. explained the reason behind the launch: “The Verséa Easy Lab™ product line was created with a mission to give millions of Americans direct access to the most essential and necessary health care services with an emphasis on prediction, prevention, and value. Currently this access is out of reach for many Americans because high-deductible health plans now dominate the marketplace. Our goal is to provide economically accessible care through the disruption of traditional care channels and “de-medicalize” basic healthcare for most Americans. By providing instant, direct access to the most desired and necessary healthcare services individuals can take control of their health, health information and level of care and intervention. This launch also strategically fits with our focus on supporting new and more accessible locations of care like urgent care clinics and independent community pharmacies.” About Verséa Health, Inc. Verséa Health, Inc. (“Verséa”) headquartered in Tampa, FL, is a U.S. healthcare company founded by experienced business executives and prominent scientific medical experts, all committed to transforming scientific discoveries into applicable healthcare & wellness solutions that are critical to improving patients’ lives

Read More

Health Technology, AI

Weave Launches AI-Driven Email Marketing Tool for Healthcare Providers

Businesswire | August 02, 2023

Weave a leading all-in-one customer experience platform for small and medium-sized healthcare businesses, today announced the launch of Email Assistant, its second AI-driven engagement product. Now available to its 27,000+ customers, Weave's AI-driven Email Assistant provides an innovative way for healthcare providers to communicate and connect with their patients and clients. By simply inputting the themes that need to be covered in the email, Weave Email Assistant will generate the email text in a matter of seconds, which can then be edited before sending. This tool allows healthcare providers to quickly create, personalize, and automate email marketing campaigns, resulting in improved patient engagement and retention, a higher patient growth rate, and increased awareness of services offered by a practice. “With digital marketing becoming an essential part of running a healthcare business, it’s important to provide simple and effective AI-driven solutions to our customers,” said Branden Neish, Chief Product & Technology Officer at Weave. “With Email Assistant, we reduce both the time requirement and anxiety often associated with creating an email marketing campaign. By harnessing the power of AI, we aim to empower healthcare providers to deliver exceptional patient experiences that drive patient loyalty and business growth.” Email marketing is an essential and often overlooked marketing avenue. According to one study, email marketing generates, on average, $36 of new business for every $1 spent, and 59% of consumers say that email marketing campaigns influence their purchasing decisions. About Weave Weave is a leading all-in-one customer experience platform for small- and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire customer journey. Weave’s software solutions transform how local businesses attract, communicate with and engage customers to grow their business. Weave has set the bar for Utah startup achievement & work culture. In the past year, Weave has been named a G2 leader in Patient Engagement, Optometry, Dental Practice Management and Patient Relationship Management software.

Read More

Health Technology, AI

WELL Health to Enter into Strategic Alliance with MCI Onehealth, Acquire Clinical Assets, and Invest in AI-Focused Data Science Business

PRNewswire | July 21, 2023

WELL Health Technologies Corp. a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that as of July 19, 2023 it has entered into an agreement to acquire clinic assets form MCI Medical clinics Inc., a subsidiary of MCI Onehealth Technologies Inc. (TSX: DRDR) ("MCI") and a subscription agreement for a convertible debenture financing in MCI which will strategically focus the MCI business around its leading AI, Data Science and Rare & Complex Disease Detection platform (the "Transaction"). "This is a major step for WELL and it's all about the power of Artificial Intelligence and how it can help solve some of the most difficult disease detection and diagnosis problems healthcare providers and patients face every day", said Hamed Shahbazi, Founder and CEO of WELL Health. "We're thrilled to enter into a number of agreements that result in a strategic alliance that will immediately position MCI OneHealth as a key national leader in the multi-billion dollar disease detection marketplace." Dr. Michael Frankel, Chief Medical Officer of WELL commented, "MCI's platform has already saved lives by discovering those 'needle in a haystack cases' and delivered value to hundreds of healthcare providers. As a physician I am excited to work with them to evolve their platform and help them expand their pool of participating physicians. I am also very excited to welcome the talented clinical staff of the clinics that will be joining the WELL Family." As part of the Transaction, WELL will acquire a significant portion of MCI's clinical assets, which are located in Southern Ontario and offer a range of primary care services, including family medicine, women's health, and other specialties. The acquisition brings more than 130 physicians to the WELL family, adding to over 3,000 providers in WELL's patient services business units across North America. The MCI clinics will be integrated with WELL's Ontario based clinic chain which is the largest owned and operated network of clinics in the province. WELL's Ontario clinics offer a breadth of care including primary care, diagnostics, allied health, and other medical subspecialties. The acquisition of these well-known and regarded primary care clinics in Ontario marks a significant milestone in WELL's national clinic expansion strategy. The clinics in this acquisition are expected to collectively contribute more than $21 million of annual revenue and are expected to contribute positive Adjusted EBITDA in 2024. Following the completion of the Transaction, WELL plans to integrate leading edge software and workflows, such as OceanMD's patient engagement tools, DoctorCare's RCM services, and WELL AI Voice, from its Practitioner Enablement Platform. WELL is also advancing a short-term bridge loan to MCI designed to ensure the company has the required resources to operate until the various transactions close. It is anticipated that closing shall occur on or around Oct 1, 2023. Once the Transaction closes, WELL will also have representation on MCI's board of directors. Upon closing of the Transaction, WELL will be a holder of MCI's convertible debentures, and shall subject to the satisfaction of certain conditions, have certain rights associated with call options granted by two shareholders of MCI for up to 30.8 million Class A Subordinate Voting Shares and 30.8 million Class B Multiple Voting shares of MCI's go-forward business. MCI plans to utilize the proceeds from this convertible debenture financing to advance their technology-enabled healthcare research offerings, placing a strong emphasis on harnessing the power of artificial intelligence for healthcare applications. This investment will be part of WELL's AI Investment Program1 where WELL stated that it will make meaningful investments in AI focused companies to help improve tools for providers and their patients. WELL is confident that our work in AI will meaningfully enhance our ESG goals and deliver societal value. Eight Capital acted as financial advisor to WELL Health in connection with the Transaction, and Clark Wilson acted as WELL Health's legal counsel. About WELL Health Technologies Corp. WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 28,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 130 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on the OTC Exchange under the symbol "WHTCF".

Read More

Medical Devices, Healthcare Analytics

Verséa Health, Inc. Launches Verséa Easy Lab™, Affordable, Highly Accurate Over-the-Counter (OTC) Product Line

businesswire | August 16, 2023

Verséa Health, Inc. (“Verséa”), a Florida-based health care company engaged in the commercialization of innovative diagnostics and therapeutics, has launched the Verséa Easy Lab™ product line of rapid, at-home, over-the-counter diagnostic tests that will be sold at retail locations nationwide. The affordable, FDA approved, and professional quality tests will enable people to check up on their health at any time and in the comfort of their homes. Verséa Easy Lab™ brings together for the first time a broad range of home use diagnostic test segments under one consumer driven national brand, and aims to put better, more rapid information on people’s health in their hands. Currently available tests provide nearly instant results and interpretation for: pregnancy, ovulation, iFOBT (colon health screening), and 6-panel drugs of abuse testing. James Olin, Chief Commercial Officer at Verséa Health, Inc. explained the reason behind the launch: “The Verséa Easy Lab™ product line was created with a mission to give millions of Americans direct access to the most essential and necessary health care services with an emphasis on prediction, prevention, and value. Currently this access is out of reach for many Americans because high-deductible health plans now dominate the marketplace. Our goal is to provide economically accessible care through the disruption of traditional care channels and “de-medicalize” basic healthcare for most Americans. By providing instant, direct access to the most desired and necessary healthcare services individuals can take control of their health, health information and level of care and intervention. This launch also strategically fits with our focus on supporting new and more accessible locations of care like urgent care clinics and independent community pharmacies.” About Verséa Health, Inc. Verséa Health, Inc. (“Verséa”) headquartered in Tampa, FL, is a U.S. healthcare company founded by experienced business executives and prominent scientific medical experts, all committed to transforming scientific discoveries into applicable healthcare & wellness solutions that are critical to improving patients’ lives

Read More

Health Technology, AI

Weave Launches AI-Driven Email Marketing Tool for Healthcare Providers

Businesswire | August 02, 2023

Weave a leading all-in-one customer experience platform for small and medium-sized healthcare businesses, today announced the launch of Email Assistant, its second AI-driven engagement product. Now available to its 27,000+ customers, Weave's AI-driven Email Assistant provides an innovative way for healthcare providers to communicate and connect with their patients and clients. By simply inputting the themes that need to be covered in the email, Weave Email Assistant will generate the email text in a matter of seconds, which can then be edited before sending. This tool allows healthcare providers to quickly create, personalize, and automate email marketing campaigns, resulting in improved patient engagement and retention, a higher patient growth rate, and increased awareness of services offered by a practice. “With digital marketing becoming an essential part of running a healthcare business, it’s important to provide simple and effective AI-driven solutions to our customers,” said Branden Neish, Chief Product & Technology Officer at Weave. “With Email Assistant, we reduce both the time requirement and anxiety often associated with creating an email marketing campaign. By harnessing the power of AI, we aim to empower healthcare providers to deliver exceptional patient experiences that drive patient loyalty and business growth.” Email marketing is an essential and often overlooked marketing avenue. According to one study, email marketing generates, on average, $36 of new business for every $1 spent, and 59% of consumers say that email marketing campaigns influence their purchasing decisions. About Weave Weave is a leading all-in-one customer experience platform for small- and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire customer journey. Weave’s software solutions transform how local businesses attract, communicate with and engage customers to grow their business. Weave has set the bar for Utah startup achievement & work culture. In the past year, Weave has been named a G2 leader in Patient Engagement, Optometry, Dental Practice Management and Patient Relationship Management software.

Read More

More featured news